Aytu Biopharma (AYTU) Debt to Equity (2016 - 2025)
Historic Debt to Equity for Aytu Biopharma (AYTU) over the last 17 years, with Q4 2025 value amounting to $1.34.
- Aytu Biopharma's Debt to Equity rose 19524.61% to $1.34 in Q4 2025 from the same period last year, while for Dec 2025 it was $1.34, marking a year-over-year increase of 19524.61%. This contributed to the annual value of $1.05 for FY2025, which is 11975.33% up from last year.
- According to the latest figures from Q4 2025, Aytu Biopharma's Debt to Equity is $1.34, which was up 19524.61% from $1.09 recorded in Q3 2025.
- Aytu Biopharma's 5-year Debt to Equity high stood at $1.34 for Q4 2025, and its period low was $0.11 during Q1 2021.
- In the last 5 years, Aytu Biopharma's Debt to Equity had a median value of $0.48 in 2024 and averaged $0.5.
- Its Debt to Equity has fluctuated over the past 5 years, first surged by 108498.16% in 2021, then tumbled by 766.43% in 2024.
- Over the past 5 years, Aytu Biopharma's Debt to Equity (Quarter) stood at $0.16 in 2021, then skyrocketed by 207.11% to $0.48 in 2022, then grew by 1.63% to $0.49 in 2023, then decreased by 6.62% to $0.45 in 2024, then soared by 195.25% to $1.34 in 2025.
- Its last three reported values are $1.34 in Q4 2025, $1.09 for Q3 2025, and $1.05 during Q2 2025.